دورية أكاديمية
أعرض في EDS

Predicting outcomes for locally advanced rectal cancer treated with neoadjuvant chemoradiation with CT-based radiomics.

التفاصيل البيبلوغرافية
العنوان: Predicting outcomes for locally advanced rectal cancer treated with neoadjuvant chemoradiation with CT-based radiomics.
المؤلفون: Wang F; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore. wang.fu.qiang@singhealth.com.sg., Tan BF; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Poh SS; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Siow TR; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Lim FLWT; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Yip CSP; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Wang MLC; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Nei W; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore., Tan HQ; Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore. tan.hong.qi@nccs.com.sg.
المصدر: Scientific reports [Sci Rep] 2022 Apr 13; Vol. 12 (1), pp. 6167. Date of Electronic Publication: 2022 Apr 13.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Neoplasms, Second Primary*/pathology , Rectal Neoplasms*/diagnostic imaging , Rectal Neoplasms*/therapy, Humans ; Neoadjuvant Therapy/methods ; Prognosis ; Rectum/pathology ; Retrospective Studies ; Tomography, X-Ray Computed
مستخلص: A feasibility study was performed to determine if CT-based radiomics could play an augmentative role in predicting neoadjuvant rectal score (NAR), locoregional failure free survival (LRFFS), distant metastasis free survival (DMFS), disease free survival (DFS) and overall survival (OS) in locally advanced rectal cancer (LARC). The NAR score, which takes into account the pathological tumour and nodal stage as well as clinical tumour stage, is a validated surrogate endpoint used for early determination of treatment response whereby a low NAR score (< 8) has been correlated with better outcomes and high NAR score (> 16) has been correlated with poorer outcomes. CT images of 191 patients with LARC were used in this study. Primary tumour (GTV) and mesorectum (CTV) were contoured separately and radiomics features were extracted from both segments. Two NAR models (NAR > 16 and NAR < 8) models were constructed using Least Absolute Shrinkage and Selection Operator (LASSO) and the survival models were constructed using regularized Cox regressions. Area under curve (AUC) and time-dependent AUC were used to quantify the performance of the LASSO and Cox regression respectively, using ten folds cross validations. The NAR > 16 and NAR < 8 models have an average AUCs of 0.68 ± 0.13 and 0.59 ± 0.14 respectively. There are statistically significant differences between the clinical and combined model for LRFFS (from 0.68 ± 0.04 to 0.72 ± 0.04), DMFS (from 0.68 ± 0.05 to 0.70 ± 0.05) and OS (from 0.64 ± 0.06 to 0.66 ± 0.06). CTV radiomics features were also found to be more important than GTV features in the NAR prediction model. The most important clinical features are age and CEA for NAR > 16 and NAR < 8 models respectively, while the most significant clinical features are age, surgical margin and NAR score across all the four survival models.
(© 2022. The Author(s).)
References: N Engl J Med. 2004 Oct 21;351(17):1731-40. (PMID: 15496622)
PLoS One. 2018 Nov 2;13(11):e0206108. (PMID: 30388114)
Eur J Radiol. 2019 Apr;113:174-181. (PMID: 30927944)
Acad Radiol. 2020 Apr;27(4):497-507. (PMID: 31285150)
Stat Med. 2006 Oct 30;25(20):3474-86. (PMID: 16220486)
Cancer Res. 2017 Nov 1;77(21):e104-e107. (PMID: 29092951)
Lancet Oncol. 2017 Mar;18(3):336-346. (PMID: 28190762)
J Clin Oncol. 2011 Dec 10;29(35):4633-40. (PMID: 22067400)
Ann Oncol. 2019 Aug 1;30(8):1298-1303. (PMID: 31192355)
Sci Rep. 2018 Aug 22;8(1):12611. (PMID: 30135549)
J Clin Oncol. 2021 Jan 10;39(2):103-106. (PMID: 33052753)
Cancer Imaging. 2019 Feb 27;19(1):11. (PMID: 30813956)
Abdom Radiol (NY). 2019 Nov;44(11):3764-3774. (PMID: 31055615)
Clin Colorectal Cancer. 2021 Mar;20(1):52-71. (PMID: 33349519)
Sci Rep. 2019 Jan 24;9(1):614. (PMID: 30679599)
Radiology. 2016 Feb;278(2):563-77. (PMID: 26579733)
Cancer. 1950 Jan;3(1):32-5. (PMID: 15405679)
Clin Radiol. 2012 Jun;67(6):546-52. (PMID: 22218409)
J Nucl Med. 2011 Mar;52(3):369-78. (PMID: 21321270)
PLoS One. 2017 Aug 10;12(8):e0182883. (PMID: 28797063)
PLoS One. 2017 Sep 21;12(9):e0178524. (PMID: 28934225)
Dis Colon Rectum. 2019 Feb;62(2):163-170. (PMID: 30451764)
Ann Oncol. 2018 Jul 1;29(7):1521-1527. (PMID: 29718095)
Sci Rep. 2019 Jul 5;9(1):9743. (PMID: 31278324)
JAMA Netw Open. 2020 Sep 1;3(9):e2015927. (PMID: 32910196)
Oncotarget. 2017 Dec 22;9(15):11999-12008. (PMID: 29552288)
J Clin Oncol. 2019 Dec 1;37(34):3212-3222. (PMID: 31150315)
Breast Cancer Res. 2017 May 18;19(1):57. (PMID: 28521821)
Theranostics. 2019 Feb 12;9(5):1303-1322. (PMID: 30867832)
Anticancer Res. 2021 Aug;41(8):3969-3976. (PMID: 34281860)
Radiology. 2020 May;295(2):328-338. (PMID: 32154773)
Med Phys. 2003 Oct;30(10):2762-92. (PMID: 14596315)
Curr Colorectal Cancer Rep. 2015;11(5):275-280. (PMID: 26321890)
Lancet Oncol. 2010 Sep;11(9):835-44. (PMID: 20692872)
Clin Cancer Res. 2016 Nov 1;22(21):5256-5264. (PMID: 27185368)
Radiother Oncol. 2019 Jun;135:153-160. (PMID: 31015162)
Sci Rep. 2020 Jul 23;10(1):12340. (PMID: 32704007)
Chin J Cancer Res. 2021 Oct 31;33(5):563-573. (PMID: 34815630)
J Clin Oncol. 2011 Aug 10;29(23):3163-72. (PMID: 21747092)
Eur Radiol. 2020 Nov;30(11):6263-6273. (PMID: 32500192)
Lancet Gastroenterol Hepatol. 2017 Jul;2(7):501-513. (PMID: 28479372)
Lancet Oncol. 2021 Jan;22(1):29-42. (PMID: 33301740)
Radiology. 2018 Jun;287(3):833-843. (PMID: 29514017)
Acad Radiol. 2019 Apr;26(4):469-479. (PMID: 30072293)
Eur Radiol. 2019 Mar;29(3):1211-1220. (PMID: 30128616)
J Natl Cancer Inst. 2014 Sep 22;106(10):. (PMID: 25249540)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Sci Rep. 2019 Oct 25;9(1):15346. (PMID: 31653909)
Sci Rep. 2018 Jul 12;8(1):10545. (PMID: 30002441)
Radiat Oncol. 2019 Mar 12;14(1):43. (PMID: 30866965)
J Stat Softw. 2011 Mar;39(5):1-13. (PMID: 27065756)
Cancers (Basel). 2019 Oct 29;11(11):. (PMID: 31671766)
J Clin Oncol. 2011 Oct 1;29(28):3753-60. (PMID: 21876084)
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762. (PMID: 28975929)
Lancet Oncol. 2021 May;22(5):702-715. (PMID: 33862000)
تواريخ الأحداث: Date Created: 20220414 Date Completed: 20220415 Latest Revision: 20220527
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9008122
DOI: 10.1038/s41598-022-10175-2
PMID: 35418656
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-022-10175-2